Changes

no edit summary
Line 69: Line 69:  
'''Loss:''' CDKN2A/CDKN2B
 
'''Loss:''' CDKN2A/CDKN2B
 
| CDKN2A/CDKN2B loss may correlate with anaplastic histology
 
| CDKN2A/CDKN2B loss may correlate with anaplastic histology
| WHO CNS Tumors (2016)PMID:25318587; PMID:23096133; PMID:21274720
+
| WHO CNS Tumors (2016)<br>
 +
PMID:25318587; PMID:23096133; PMID:21274720
 
|-
 
|-
 
|Glioblastoma, WHO grade IV
 
|Glioblastoma, WHO grade IV
Line 96: Line 97:  
|Overall poor prognosis regardless of subgroup
 
|Overall poor prognosis regardless of subgroup
 
|PMCID:3280796; PMID:24705254; PMID:24705252 PMID:27048880; PMID:26175967; PMID:24705251; PMID:28966033
 
|PMCID:3280796; PMID:24705254; PMID:24705252 PMID:27048880; PMID:26175967; PMID:24705251; PMID:28966033
 +
|-
 +
|'''EPENDYMOMA'''<br>
 +
(in order of increasing WHO grade)
 +
|
 +
|'''DNA-based methylation classifies''' tumors across anatomical sites (posterior fossa, supratentorial, spinal), grades and age groups
 +
|'''Fusion:''' YAP1 fusions (supratentorial tumors)<br>
 +
'''Mutation:''' NF2 (spinal tumors)<br>
 +
'''Loss:''' CDKN2A
 +
|Intracranial (in children, 90%) or spinal tumors; Histological distinction between WHO grade II and III is of questionable relevance; Prognostic differences among tumors suggested on the basis of methylation analysis
 +
|WHO CNS Tumors (2016)<br>
 +
PMID:25965575; PMID:21627842; PMID:24939246; PMID:22516549
 +
|-